Secrets and Lies in a Silicon Valley Startup
Narrated by Will Damron / 11 hours 36 minutes
“Theranos was a startup that set itself apart from the bevy of others in Silicon Valley. Its cause was noble, manufacturing revolutionary medical technology that could run a menu of blood tests on only a finger stick's worth of blood, eliminating the need for large painful needles. There was only one problem: the technology didn't exist. Painstakingly researched but still accessible to the medical layman, Pulitzer prize-winning journalist John Carreyrou investigates the meteoric rise and fall of Theranos, exploring how the company managed to fool the public, investors, board members like George Schultz and Henry Kissinger, and even Barack Obama. A must for true crime podcast fans, especially if you find yourself needing a break from the more gruesome stuff.”Maggie, Square Books
NEW YORK TIMES BEST SELLER • NAMED ONE OF THE BEST BOOKS OF THE YEAR BY: NPR, The New York Times Book Review, Time, Wall Street Journal, Washington Post • The McKinsey Business Book of the Year
The full inside story of the breathtaking rise and shocking collapse of Theranos, the one-time multibillion-dollar biotech startup founded by Elizabeth Holmes—now the subject of the HBO documentary The Inventor—by the prize-winning journalist who first broke the story and pursued it to the end.
“The story is even crazier than I expected, and I found myself unable to put it down once I started. This book has everything: elaborate scams, corporate intrigue, magazine cover stories, ruined family relationships, and the demise of a company once valued at nearly $10 billion.” —Bill Gates
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.7 billion. There was just one problem: The technology didn’t work.
A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.